Featured
Revive Therapeutics Ltd (OTCMKTS:RVVTF) Receives Approval For Phase 3 Clinical Study Of Bucillamine From FDA: Inks A Pact With AMS To Facilitate Trial To Treat COVID-19
September 3, 2020 |
|